scholarly journals Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

Cancer ◽  
2009 ◽  
Vol 115 (20) ◽  
pp. 4783-4794 ◽  
Author(s):  
Philippe Metellus ◽  
Bema Coulibaly ◽  
Isabelle Nanni ◽  
Frederic Fina ◽  
Nathalie Eudes ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Dna Methyltransferase ◽  
Recurrent Glioblastoma ◽  
Prognostic Impact ◽  
Recurrent Glioblastoma Multiforme ◽  
Methylguanine Dna Methyltransferase ◽  
Carmustine Wafer

scholarly journals Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

2002 ◽  
Vol 13 (5) ◽  
pp. 777-780 ◽  
Author(s):  
C. Twelves ◽  
M. Campone ◽  
B. Coudert ◽  
M. Van den Bent ◽  
M. de Jonge ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Recurrent Glioblastoma ◽  
Recurrent Glioblastoma Multiforme

scholarly journals NIMG-37. DELAYED PSEUDOPROGRESSION IN TWO PATIENTS UNDERGOING TTFIELDS TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMA

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii155-ii156
Author(s):  
Allison Lowman ◽  
Sarah Hurrell ◽  
Samuel Bobholz ◽  
Jennifer Connelly ◽  
Elizabeth Cochran ◽  
...  
Keyword(s):  
Dna Methyltransferase ◽  
Radiographic Progression ◽  
Methylation Status ◽  
Underlying Mechanism ◽  
Recurrent Glioblastoma ◽  
Newly Diagnosed ◽  
Methylguanine Dna Methyltransferase ◽  
Specific Effects ◽  
Newly Diagnosed Glioblastoma ◽  
Associated Risk Factors

Abstract PURPOSE Tumor treatment fields (TTFields) are approved by the FDA for newly diagnosed as well as recurrent glioblastoma (GBM). TTFields have been shown to extend survival by 4.9 months in newly diagnosed GBM, and a landmark overall survival rate of 13% at 5 years. However, the specific effects remain widely unknown, which has prevented widespread clinical use of this treatment. METHODS This case study examines two glioblastoma patients, IDH-1 wildtype, MGMT unmethylated, that received TTFields (Optune) in addition to maintenance temozolomide (TMZ) following radiation (RT). Both cases were followed using standard MR imaging. Second resections were performed due to radiographic progression of contrast enhancement. RESULTS Although imaging was concerning for tumor progression, pathology showed only treatment effect, ultimately leading to the diagnosis of pseudoprogression. Both patients fell outside the normal expected timeline for chemo-radiation induced pseudoprogression. Based on the pathology, both patients resumed treatment with TMZ/TTFields. One patient expired at 25 months and one is still alive. CONCLUSIONS Pathologic confirmation was essential for guiding further treatment and allowed patients to continue treatment that was effective despite contrary indications on imaging. These findings suggest that pathological confirmation should be strongly considered in patients receiving TMZ/TTFields who develop radiographic progression, potentially with a less invasive biopsy procedure. Future studies should look to characterize the underlying mechanism of interaction between TTFields/TMZ and quantify the prevalence, associated risk factors and whether there is a genotype more susceptible. Both patients reported here had O(6)-methylguanine-DNA methyltransferase (MGMT) unmethylated GBM, and while about 60% of glioblastomas are diagnosed likewise, it is possible that MGMT methylation status plays a role in TTFields response. Better characterization of this phenomenon will improve treatment guidance, potentially reducing unnecessary surgeries and the discontinuance of successful therapies.

scholarly journals RTRB-09SALVAGE STEREOTACTIC RADIOSURGERY TO RECURRENT GLIOBLASTOMA MULTIFORME FOLLOWING PRIOR RADIOTHERAPY

2015 ◽  
Vol 17 (suppl 5) ◽  
pp. v197.1-v197
Author(s):  
Douglas Holt ◽  
Mark Bernard ◽  
Kimmen Quan ◽  
David Clump ◽  
Johnathan Engh ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Stereotactic Radiosurgery ◽  
Recurrent Glioblastoma ◽  
Recurrent Glioblastoma Multiforme

Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: a multicenter experience

2009 ◽  
Vol 32 (4) ◽  
pp. 417-424 ◽  
Author(s):  
Alan T. Villavicencio ◽  
Sigita Burneikienė ◽  
Pantaleo Romanelli ◽  
Laura Fariselli ◽  
Lee McNeely ◽  
...  
Keyword(s):  
Glioblastoma Multiforme ◽  
Stereotactic Radiosurgery ◽  
Recurrent Glioblastoma ◽  
Newly Diagnosed ◽  
Recurrent Glioblastoma Multiforme
Sign in / Sign up

Export Citation Format

Share Document